Literature DB >> 28620009

Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk.

Anita Villani1, Mary-Louise C Greer2, Jennifer M Kalish3, Akira Nakagawara4, Katherine L Nathanson5, Kristian W Pajtler6,7, Stefan M Pfister6,7, Michael F Walsh8, Jonathan D Wasserman9, Kristin Zelley10, Christian P Kratz11.   

Abstract

In October 2016, the American Association for Cancer Research held a meeting of international childhood cancer predisposition syndrome experts to evaluate the current knowledge of these syndromes and to propose consensus surveillance recommendations. Herein, we summarize clinical and genetic aspects of RASopathies and Sotos, Weaver, Rubinstein-Taybi, Schinzel-Giedion, and NKX2-1 syndromes as well as specific metabolic disorders known to be associated with increased childhood cancer risk. In addition, the expert panel reviewed whether sufficient data exist to make a recommendation that all patients with these disorders be offered cancer surveillance. For all syndromes, the panel recommends increased awareness and prompt assessment of clinical symptoms. Patients with Costello syndrome have the highest cancer risk, and cancer surveillance should be considered. Regular physical examinations and complete blood counts can be performed in infants with Noonan syndrome if specific PTPN11 or KRAS mutations are present, and in patients with CBL syndrome. Also, the high brain tumor risk in patients with L-2 hydroxyglutaric aciduria may warrant regular screening with brain MRIs. For most syndromes, surveillance may be needed for nonmalignant health problems. Clin Cancer Res; 23(12); e83-e90. ©2017 AACRSee all articles in the online-only CCR Pediatric Oncology Series. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28620009     DOI: 10.1158/1078-0432.CCR-17-0631

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

Review 1.  JMML genomics and decisions.

Authors:  Charlotte M Niemeyer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

3.  De novo FBXO11 mutations are associated with intellectual disability and behavioural anomalies.

Authors:  Daniel Fritzen; Alma Kuechler; Mona Grimmel; Jessica Becker; Sophia Peters; Marc Sturm; Hela Hundertmark; Axel Schmidt; Martina Kreiß; Tim M Strom; Dagmar Wieczorek; Tobias B Haack; Stefanie Beck-Wödl; Kirsten Cremer; Hartmut Engels
Journal:  Hum Genet       Date:  2018-05-23       Impact factor: 4.132

4.  De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability, Short Stature, and Facial Dysmorphism.

Authors:  Illja J Diets; Roos van der Donk; Kristina Baltrunaite; Esmé Waanders; Margot R F Reijnders; Alexander J M Dingemans; Rolph Pfundt; Anneke T Vulto-van Silfhout; Laurens Wiel; Christian Gilissen; Julien Thevenon; Laurence Perrin; Alexandra Afenjar; Caroline Nava; Boris Keren; Sarah Bartz; Bethany Peri; Gea Beunders; Nienke Verbeek; Koen van Gassen; Isabelle Thiffault; Maxime Cadieux-Dion; Lina Huerta-Saenz; Matias Wagner; Vassiliki Konstantopoulou; Julia Vodopiutz; Matthias Griese; Annekatrien Boel; Bert Callewaert; Han G Brunner; Tjitske Kleefstra; Nicoline Hoogerbrugge; Bert B A de Vries; Vivian Hwa; Andrew Dauber; Jayne Y Hehir-Kwa; Roland P Kuiper; Marjolijn C J Jongmans
Journal:  Am J Hum Genet       Date:  2019-03-28       Impact factor: 11.025

5.  Hyperinsulinemic hypoglycemia in seven patients with de novo NSD1 mutations.

Authors:  Katheryn Grand; Christina Gonzalez-Gandolfi; Amanda M Ackermann; Deema Aljeaid; Emma Bedoukian; Lynne M Bird; Diva D De Leon; Jullianne Diaz; Robert J Hopkin; Sejal P Kadakia; Beth Keena; Karen O Klein; Ian Krantz; Eyby Leon; Katherine Lord; Carey McDougall; Livija Medne; Cara M Skraban; Charles A Stanley; Jennifer Tarpinian; Elaine Zackai; Matthew A Deardorff; Jennifer M Kalish
Journal:  Am J Med Genet A       Date:  2019-02-04       Impact factor: 2.802

6.  Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum.

Authors:  Marialetizia Motta; Luca Pannone; Francesca Pantaleoni; Gianfranco Bocchinfuso; Francesca Clementina Radio; Serena Cecchetti; Andrea Ciolfi; Martina Di Rocco; Mariet W Elting; Eva H Brilstra; Stefania Boni; Laura Mazzanti; Federica Tamburrino; Larry Walsh; Katelyn Payne; Alberto Fernández-Jaén; Mythily Ganapathi; Wendy K Chung; Dorothy K Grange; Ashita Dave-Wala; Shalini C Reshmi; Dennis W Bartholomew; Danielle Mouhlas; Giovanna Carpentieri; Alessandro Bruselles; Simone Pizzi; Emanuele Bellacchio; Francesca Piceci-Sparascio; Christina Lißewski; Julia Brinkmann; Ronald R Waclaw; Quinten Waisfisz; Koen van Gassen; Ingrid M Wentzensen; Michelle M Morrow; Sara Álvarez; Mónica Martínez-García; Alessandro De Luca; Luigi Memo; Giuseppe Zampino; Cesare Rossi; Marco Seri; Bruce D Gelb; Martin Zenker; Bruno Dallapiccola; Lorenzo Stella; Carlos E Prada; Simone Martinelli; Elisabetta Flex; Marco Tartaglia
Journal:  Am J Hum Genet       Date:  2020-07-27       Impact factor: 11.025

Review 7.  Is MRI imaging in pediatric age totally safe? A critical reprisal.

Authors:  Sergio Salerno; Claudio Granata; Marco Trapenese; Vittorio Cannata; Davide Curione; Maria Camilla Rossi Espagnet; Andrea Magistrelli; Paolo Tomà
Journal:  Radiol Med       Date:  2018-05-03       Impact factor: 3.469

8.  NGS testing for cardiomyopathy: Utility of adding RASopathy-associated genes.

Authors:  Ozge Ceyhan-Birsoy; Maya M Miatkowski; Elizabeth Hynes; Birgit H Funke; Heather Mason-Suares
Journal:  Hum Mutat       Date:  2018-05-16       Impact factor: 4.878

9.  Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.

Authors:  Ikumi Umeki; Tetsuya Niihori; Taiki Abe; Shin-Ichiro Kanno; Nobuhiko Okamoto; Seiji Mizuno; Kenji Kurosawa; Keisuke Nagasaki; Makoto Yoshida; Hirofumi Ohashi; Shin-Ichi Inoue; Yoichi Matsubara; Ikuma Fujiwara; Shigeo Kure; Yoko Aoki
Journal:  Hum Genet       Date:  2018-10-27       Impact factor: 4.132

Review 10.  Overgrowth syndromes - clinical and molecular aspects and tumour risk.

Authors:  Frédéric Brioude; Annick Toutain; Eloise Giabicani; Edouard Cottereau; Valérie Cormier-Daire; Irene Netchine
Journal:  Nat Rev Endocrinol       Date:  2019-05       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.